Skip to main content

Engineering the protein corona on RNA nanoparticles for improved nucleic acids-based therapies delivery

Project description

Improving nanoparticle-based drug delivery

Recent advances in nanotechnology have paved the way for the use of nanoparticles in cancer therapy as drug delivery vehicles. Despite the advantages of nanoparticle drug delivery, including high selectivity and reduced toxicity, there are various aspects to the process that remain elusive, such as the acquisition of proteins upon in vivo injection. The EU-funded NanoRNA_PC project will employ state-of-the-art methodologies to characterise the protein corona formed on RNA nanoparticles upon interaction with biological components. Understanding the composition of the protein corona on nanoparticles is expected to improve their design as well as their biological outcome.


Net EU contribution
€ 212 933,76
The Imperial College White City Inc Innovation Hub
W12 0BZ London
United Kingdom

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00